德展健康(000813.SZ)拟增资入股北京东方略 在肿瘤领域进行持续布局
德展健康(000813.SZ)公布,拟对北京东方略生物医药科技股份有限公司进行增资,以其合法拥有的现金出资3亿元人民币(下同)认购标的公司此次新增3,615万股股份,超出新增注册资本的金额2.64亿元计入标的公司的资本公积。
北京东方略原股东一致同意将北京东方略的注册资本由1.2亿元增至1.56亿元。增资後,德展健康持有北京东方略23.22%股权,为其第一大股东。公司表示,此次交易为公司在肿瘤领域进行持续布局,可帮助公司丰富自有产品线和拓展市场。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.